Clinical Read2026-06-12

Tacabrutideg (BGB-16673-101) - (CaDAnCe-101)

BeiGene Ltd.BGNE
Indication
Relapsed or refractory (R/R) CLL/SLL
Stage
phase1
Event
Phase 1